In recent news, Hims & Hers Health has announced the launch of access to compounded GLP-1 weight loss injections on their platform. The company, which offers direct-to-consumer treatments for various conditions such as erectile dysfunction and hair loss, recently introduced a weight loss program in December. However, GLP-1 medications were not previously included in the program.
Customers can now obtain compounded GLP-1 medications with a prescription from a licensed healthcare provider through the Hims & Hers platform. The company plans to offer branded GLP-1 medications to its customers once a consistent supply is available. Oral medication kits from Hims & Hers start at $79 a month, while compounded GLP-1 injections will begin at $199 a month.
Even before the addition of compounded GLP-1s, Hims & Hers projected in its fourth-quarter earnings report that the weight loss program would generate over $100 million in revenue by 2025. The company anticipates providing updated guidance in their upcoming earnings report.
The GLP-1 market has been experiencing supply constraints due to regulatory approval and increased coverage of these drugs. GLP-1 medications mimic a gut-produced hormone that regulates appetite and blood sugar levels. Compounding pharmacies can create versions of these medications if they meet specific FDA requirements.
Hims & Hers CEO Andrew Dudum expressed confidence that customers will have steady access to the compounded GLP-1 medications. The company has spent the past year studying the GLP-1 supply chain and partnered with a major generic manufacturer with FDA oversight. This partnership ensures consistent volume and supply for consumers, Dudum shared in an interview.
